TSX: HSM     OTC: HSDT

Call us: +1 215-809-2018

divisionBanner

A division of Helius Medical Technologies (Helius), NeuroHabilitation is developing a breakthrough technology as a potential treatment for neurological symptoms caused by disease or trauma.

In 2013, NeuroHabilitation signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense to develop and manage clinical and regulatory activities for the PoNS™ device and CN-NINM technologies.

The PoNSTM Device

PoNS uses cranial nerve noninvasive neuromodulation (CN-NINM) to potentially alter the capacity, organization and function of brain structures.

Learn About The PoNS™ Device